Are patients with diabetes more susceptible to open angle glaucoma?
April 1st 2009Dr Vikas Shankar has found that in the diabetic population with OAG, the optic nerve damage occurs at a lower intraocular pressure in comparison with the non-diabetic OAG population and asks: does screening hold the key?
Prosthetic implants to oxygenate retinal tissue
April 1st 2009Blindness in millions of people with diseases that starve eye tissue and nerves of oxygen might be averted with a procedure being developed by researchers at Oak Ridge National Laboratory, the University of Southern California and the University of Tennessee.
Red meat consumption associated with early AMD
March 25th 2009According to Eye Research Australia researchers at the University of Melbourne, a high intake of fresh and processed red meat is positively associated with early AMD, the leading cause of blindness among older people. Diet has often been postulated to alter the risk of AMD.
New wet AMD treatment a step closer
March 25th 2009The CABERNET (CNV Secondary to AMD Treated with Beta RadiatioN Epiretinal Therapy) clinical trial is pivotal to establishing the safety and effectiveness of a beta radiation based focal epimacular brachytherapy device. Its development in bringing a paradigm shift in the way retina specialists treat wet AMD patients moved a step closer as Neovista Inc. secured more than $18 million in its Series D private venture funding round.
Patient enrolment completed for prevention of corneal transplant rejection trial
March 25th 2009Lux Biosciences has just completed its enrolment in the company's Phase III LUCIDA (LUx Corneal Transplant Implant Development and Advancement of Therapy) clinical trial programme for LUMITECT (LX201), a silicone matrix ocular (episcleral) implant designed to provide the continuous release for one year of therapeutic levels of cyclosporine A locally to the eye to prevent corneal transplant rejection.
Novagali technologies allow greater drug access to the posterior of the eye
March 25th 2009According to research analysts it is estimated that as little as five percent of a topically applied drug ever reaches the intraocular tissues due to drug loss as the result of tearing, lacrimal fluid-eye barriers, and blood-ocular barriers.
Testing dry eye diagnostic system
March 18th 2009The TearLab Osmolarity Core Validation Study, a multicentre international clinical study assessing the efficacy of the TearLab Osmolarity System for the diagnosis of dry eye disease, has been launched by the system's maker, OccuLogix Inc, and sponsored by Alcon.